Toronto, ON – Biotech company Arius Research says that Dr Daniel Pereira has joined it as vice president of research.
Dr Pereira previously spent eight years at ImClone Systems where he was director of the tumour biology department. In his most recent role there, he directed antibody target identification efforts, lead and authored a publication on the RON antibody project, and was a member of the steering committee for the company’s antibody projects.
“We are delighted to welcome Dr Pereira to Arius as a senior member of the management team,” says Dr David S Young, president and chief scientific officer of Arius.
Dr Pereira brings extensive research experience in discovery, characterization and development of anti-cancer antibodies. Reporting to Dr Young, he will manage a team of scientists and will be responsible for continued innovation to the companys platform and pre-clinical characterization of Arius’ functional antibodies.
In 1994, Dr Pereira received his doctorate from McMaster University where he was a doctoral fellow of the Cancer Research Society of Canada. He later joined Dr John Dick’s laboratory at the University of Toronto as a Terry Fox post-doctoral research fellow of the National Cancer Institute of Canada. There he identified genetic factors related to leukemia and developed in vitro and in vivo models for the study of the disease.
Arius is a biotechnology company dedicated to personalizing cancer therapy through the discovery and development of novel anticancer monoclonal antibodies (MAbs).